Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 1

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 867Carcinoma, Non-Small-Cell Lung 637Prostatic Neoplasms 516Multiple Myeloma 441Neoplasms 425Leukemia, Myeloid, Acute 377Lymphoma 356Leukemia 335Melanoma 333Neoplasm Metastasis 321Lung Neoplasms 308Lymphoma, Non-Hodgkin 302Leukemia, Lymphocytic, Chronic, B-Cell 301Colorectal Neoplasms 281Ovarian Neoplasms 264Pancreatic Neoplasms 249Recurrence 240Precursor Cell Lymphoblastic Leukemia-Lymphoma 239Myelodysplastic Syndromes 233Glioblastoma 212Hodgkin Disease 201Lymphoma, Large B-Cell, Diffuse 197Lymphoma, Follicular 195Brain Neoplasms 194Carcinoma, Renal Cell 189Head and Neck Neoplasms 187Squamous Cell Carcinoma of Head and Neck 186Lymphoma, Mantle-Cell 171Sarcoma 158Fallopian Tube Neoplasms 139

Interventions

sapanisertib 1onvansertib 1abiraterone 1abemaciclib 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × Metastatic Castration-Resistant Prostate Cancer × Clear all
NCT03414034 2024-11-07

Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer

Cardiff Oncology

Phase 2 Completed
72 enrolled 21 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT04408924 2024-06-25

CYCLONE 1

Eli Lilly and Company

Phase 2 Completed
44 enrolled 21 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT02091531 2019-11-21

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
9 enrolled 10 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡